Arthneeti
All Q1 FY27 results →
MH

Metropolis Healt

Q1 FY27Healthcare Services

Metropolis Healt Q1 FY27 earnings call: Revenue & Margins

Q1 FY27 earnings call: what management said on revenue, margins and capex.

Price₹567
Market cap₹11.6K Cr
P/E55.5
Updated25 Aug 2026
Read3 min read

What the Q1 FY27 call signalled

2 of 3 strong

RevenueModerate growth
MarginMargins up
CapexCapex planned

The short version

Metropolis expects a medium-term compounded annual growth rate (CAGR) of 14%-15% in revenue. Management remains extremely optimistic about FY 2026-2027 growth and margin expansion.

From Metropolis Healt's Q1 FY27 earnings-call transcript · updated 25 Aug 2026.

Revenue & Sales Performance

Moderate growth
  • Metropolis expects a medium-term compounded annual growth rate (CAGR) of 14%-15% in revenue.
  • Patient volume growth is projected at 9%-10%, driven by network expansion into Tier-2 and Tier-3 towns and improved productivity of existing centers.
  • Network expansion continues with plans to add over 500 centers in the current financial year, deepening presence in 750 towns.
  • Balanced growth seen across mature centers and ramp-up in new centers.
  • B2C and B2B segments both contributing healthily, with B2C revenue growing 18% and B2B growing 15% year-on-year in Q1 FY 2027.

2 more points from Metropolis Healt's call on revenue

Create a free account to keep reading this call

Profitability & Margins

See what Metropolis Healt said on profitability & margins — free account, 30 seconds.

Capital Expenditure Plans

Capex planned
  • Last year, Metropolis Healthcare spent around INR 65 crores on CAPEX for the entire Group, including acquired entities.
  • CAPEX for the current year is expected to be in similar lines, i.e., approximately INR 65 crores.
  • The Company is deepening presence in existing 750 towns rather than expanding beyond, limiting additional cost pressures.
  • Lab expansion agenda has been on hold for the last five quarters, avoiding extra CAPEX from new labs.
  • The focus remains on increasing productivity and operating leverage in existing centers.

2 more points from Metropolis Healt's call on capex

Create a free account to keep reading this call

Top-ranked in Healthcare Services

Ranked on what management guided this quarter

Guidance-ranked
1Health X Platform
Rev 1Mar 1
2Chandan Healthca
Rev 1Mar 3
3
Rev 2Mar 1
4
Rev 2Mar 1
5
Rev 2Mar 2
Sign up free to see 3 moreTakes 30 seconds · no cardSign up

Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.

Fundraising & Capital Structure

See what Metropolis Healt said on fundraising & capital structure — free account, 30 seconds.

Order Book & Pipeline

See what Metropolis Healt said on order book & pipeline — free account, 30 seconds.

Metropolis Healt — Quarterly revenue & net profit

Revenue Net profit
Mar 2025Q4 FY25
Jun 2025Q1 FY26
Sep 2025Q2 FY26
Dec 2025Q3 FY26
Mar 2026Q4 FY26
Jun 2026Q1 FY27

Reported quarterly figures (₹ Cr). Latest (Q1 FY27): revenue ₹450 Cr, net profit ₹57 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.

Full financials →

Continue your research

What Metropolis Healt's management said in earlier quarters

Others in Healthcare Services this season

  • Aatmaj Health (Q1 FY27)

    Revenue for Q1 FY 2026-27: ₹8.13 crore . Key investor presentation takeaways from Aatmaj Healthcare Ltd's Q1 FY27 investor presentation — and how it ranks again

  • Asarfi Hospital Ltd (Q1 FY27)

    Q1'FY27 consolidated revenue from operations: ₹47.5 Cr, up 32.8% YoY (vs ₹35.7 Cr in Q1'FY26) . Key investor presentation takeaways from Asarfi Hospital Ltd's Q

  • KMC Speciality (Q1 FY27)

    Q1 FY'27 Revenue from operations: INR 91.8 Cr, up 38% YoY from INR 66.6 Cr in Q1 FY'26. Key concall takeaways from KMC Speciality Hospitals (India) Ltd's Q1…

  • 3B Blackbio (Q1 FY27)

    Q1 2026-27 revenue from operations: ₹3,205.73 Lakh (including Coris sales of ₹862.83 Lakh) vs ₹1,996.06 Lakh in Q1 2025-26 — YoY growth approx. Key concall…

Compare:vs Apollo Hospitalsvs Max Healthcarevs Manipal Health

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →

Arthneeti Pro · Annual

Metropolis Healt and 15K+ more earnings calls,
for less than your morning chai

a day

Every earnings call, ranking and concall Q&A across all four results seasons.

Secure Razorpay payment · instant access

Frequently Asked Questions

What were Metropolis Healt Q1 FY27 results?

Metropolis expects a medium-term compounded annual growth rate (CAGR) of 14%-15% in revenue. Management remains extremely optimistic about FY 2026-2027 growth and margin expansion.

What is Metropolis Healt share price analysis?

Metropolis Healt currently shows a below-average growth signal. The stock trades at a P/E of 55.5 with a market cap of ₹11,550 Cr. Investors should review the full earnings analysis for detailed insights.

Is Metropolis Healt planning capital expenditure?

Last year, Metropolis Healthcare spent around INR 65 crores on CAPEX for the entire Group, including acquired entities.

Keep Metropolis Healt on your radar — track it to get its next earnings analysis in your feed.

This analysis is AI-generated based on publicly available earnings data and the company's earnings call transcript. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.